Peptonic Medical AB, a Swedish medtech company, has successfully concluded its Rights Issue, achieving a subscription rate of 62.1%. This outcome translates to 71,562,122 units subscribed, bringing in approximately SEK 16.5 million before issue costs. The Rights Issue attracted interest both from existing shareholders and new investors, with 44.8% of subscriptions made through unit rights and 9.8% without.

The company offered each unit at a subscription price of SEK 0.0046 per share, comprising 50 newly issued shares per unit. Notably, top-down underwriters contributed to 7.5% of the total subscriptions, underscoring confidence in Peptonic's strategic direction.

Peptonic's share capital has increased significantly, with an addition of 3,578,106,100 shares, elevating the total share count to 9,337,409,114. This capital boost is poised to support Peptonic's ambitious growth strategy, focusing on expanding its geographic footprint in the U.S. and Europe, and enhancing its product portfolio.

The funds raised will be strategically deployed to bolster Peptonic's market position, particularly through its brands VagiVital and Vernivia, which offer innovative solutions for women's intimate health. The company's focus on clinically proven self-care products aligns well with current health trends, potentially driving future growth.

Given the successful outcome of the Rights Issue and Peptonic's solid strategic plans, the recommendation for investors is to hold their positions. The company is on a promising growth trajectory, and maintaining investments could yield positive returns as Peptonic continues to execute its expansion and product development strategies.